Clinical trials
Breast clinical trials
Below are recruiting breast clinical trials, each written for real people, not researchers. We’re tracking 2,627 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06874933RecruitingPhase 2
Chemo plus anlotinib and benmelstobart for HR+/HER2- breast cancer
This trial tests adding anlotinib (a targeted therapy) and benmelstobart (an immunotherapy) to standard chemotherapy before surgery for a specific type of breast cancer. It may help shrink tumors and improve outcomes for patients whose tumors have certain markers.
Hangzhou, ZhejiangAges 18–75 - NCT06879704Recruiting
Predicting breast cancer response to pre-surgery therapy with X-rays
This trial uses special imaging before and after treatment to see if it can predict how well triple-negative breast cancer responds to chemotherapy plus immunotherapy given before surgery. Participation could help doctors tailor future treatments.
RouenAges 18–75 - NCT06875128RecruitingPhase 2
Liver-directed chemo with standard chemo for breast cancer
This trial tests if giving a high dose of chemotherapy directly into the liver, followed by standard chemotherapy, is safe and works better than standard chemo alone for people with breast cancer that has spread mostly to the liver.
Tampa, FloridaAges 18 years+ - NCT06402435RecruitingPhase 2
Combination therapy before surgery for hormone positive breast cancer
This trial tests a new combination of treatments given before surgery for hormone receptor positive, HER2 negative breast cancer. It uses stereotactic body radiation therapy (SBRT), chemotherapy, and an investigational drug called AK112 to shrink tumors and make surgery easier.
Wuhan, HubeiAges 18 years+ - NCT06860529RecruitingPhase 2
Immunotherapy plus chemo for early-stage HR+/HER2- breast cancer
This trial tests adding the immunotherapy drug serplulimab to standard chemotherapy for people with early-stage HR-positive, HER2-negative breast cancer. It aims to see if this combination can improve outcomes before surgery.
Zhengzhou, HenanAges 18 years+ - NCT06858449Recruiting
Exercise and protein during chemo for breast cancer
This study tests whether adding resistance training (like lifting weights) along with a protein shake after workouts can help women with breast cancer maintain muscle and bone health while they receive chemotherapy before surgery.
Pittsburgh, PennsylvaniaAges 20–89 - NCT06195865Recruiting
Comparing body-tissue vs. implant breast reconstruction
This trial compares two types of breast reconstruction after mastectomy: using your own tissue (DIEP flap) versus using an implant. It aims to see which gives better results.
GothenburgAges 18 years+ - NCT04889469Recruiting
Breast size reduction for people with heavy, painful breasts
This study looks at who might qualify for breast reduction surgery in Sweden’s public healthcare system. It aims to match people with very large breasts and related symptoms to treatment criteria, and compare groups who do and do not meet those standards.
GothenburgAges 18–75 - NCT05222100Recruiting
Study how breast implants affect mammogram screening
This trial looks at whether having breast implants changes what happens during routine breast cancer screening with mammograms. It may help improve how screening is done and understood for people with implants.
GothenburgAges 40–75 - NCT06856343Recruiting
Olaparib for early breast cancer treatment study
This study looks at how well the drug Olaparib works in real-world settings for patients with early breast cancer that is HER2-negative. It aims to better understand treatment outcomes.
Clermont-Ferrand, Auvergne-Rh ne-AlpesAges 18 years+ - NCT06846814Enrolling by invitation
Ultrasound after contrast mammography to check extra breast lesions
This trial tests whether doing a follow-up ultrasound after a special type of mammogram (contrast-enhanced mammography) can better understand extra breast spots that need more checking. It might help doctors give a clearer diagnosis.
NaplesAges 18 years+ - NCT06841354RecruitingPhase 3
Sac-TMT alone or with pembrolizumab for advanced triple-negative breast cancer
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Mobile, AlabamaAges 18 years+ - NCT06839547Recruiting
Testing a new drug with radiation for advanced breast cancer brain tumors
This study looks at how well a new anti-tumor drug works when given along with radiation therapy for people whose advanced breast cancer has spread to the brain. It may help the radiation work better and control the cancer longer.
BeijingAges 18 years+ - NCT06843096Enrolling by invitation
Special mammogram for finding breast cancer when origin is unknown
This trial uses a special mammogram with contrast dye to look for breast cancer in people who have cancer that started somewhere unknown (called Cancer of Unknown Primary). It may help find if the breast is the source, which could guide treatment.
RomeAges 18 years+ - NCT06845319RecruitingPhase 2
Chemo-immunotherapy before surgery for triple-negative breast cancer
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
Charleston, South CarolinaAges 18 years+ - NCT06843681Enrolling by invitationPhase 2
Trastuzumab and Chemo Before Surgery for HER2-Positive DCIS
This trial tests giving trastuzumab (a targeted drug) plus a chemotherapy drug called a taxane before surgery for women with HER2-positive ductal carcinoma in situ (DCIS), an early form of breast cancer. The goal is to see if this combination can shrink or eliminate the cancer before surgery.
Guangzhou, GuangdongAges 18–70 - NCT06839560RecruitingPhase 2
Immunotherapy plus chemotherapy and radiation for advanced breast cancer with brain metastases
This trial tests a combination of a PD-L1 inhibitor with a low-dose chemotherapy regimen and either immediate or delayed radiation therapy for people with HER2-negative breast cancer that has spread to the brain. The goal is to see if this approach helps shrink brain tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06838130Enrolling by invitation
AI study of breast density and enhancement patterns
This study uses artificial intelligence to analyze breast density and background enhancement from breast imaging exams to better understand their patterns. It may help improve how breast cancer risk is assessed in the future.
NaplesAges 18 years+ - NCT06830720Recruiting
Kisqali with hormone therapy for early-stage breast cancer
This study looks at how well Kisqali (ribociclib) combined with hormone therapy works after surgery for people with early-stage HR+ HER2- breast cancer that has a high chance of coming back. It aims to gather real-world data on different treatment options.
Wiener Neustadt, Lower AustriaAges 18–100 - NCT06830889RecruitingPhase 3
BL-M07D1 vs T-DM1 for HER2-positive breast cancer after neoadjuvant therapy
This trial tests whether a new drug called BL-M07D1 works better than an existing drug, T-DM1, for people with HER2-positive breast cancer who still have cancer cells after initial treatment (neoadjuvant therapy). The goal is to prevent the cancer from coming back.
Nanjing, JiangsuAges 18–75 - NCT06833853Recruiting
Blood test study for women with advanced breast cancer
This study looks at a blood test that measures certain markers on cancer cells (CTCs) and genetic material in the blood (cfDNA/RNA) in women with metastatic breast cancer. It aims to better understand the cancer and guide treatment decisions.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06827613RecruitingPhase 1/Phase 2
Study of invikafusp alfa plus sacituzumab govitecan for advanced solid tumors
This trial tests a new drug combination for people with advanced breast cancer (triple-negative or hormone receptor-positive). The goal is to see if the combination helps shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06830382Recruiting
HER2-PET scan for metastatic breast cancer treatment
This trial uses a special PET scan (HER2-PET) to see if a targeted drug (trastuzumab deruxtecan) works better for your type of metastatic breast cancer. The goal is to match the treatment to how much HER2 protein your tumors show.
SolnaAges 18 years+ - NCT06833255Recruiting
Support Program for Black Women Breast Cancer Survivors
This program pairs Black women who have completed breast cancer treatment with support to help them transition into survivorship. It offers mentorship based on how recently you finished treatment, with priority for those who had limited support or who identify as African American.
Buffalo, New YorkAges 18 years+
Hear when a new Breast trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast?
- Yes. Clin2 currently lists 2,627 recruiting breast studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.